◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksE › EAPI

Euroapi S.A. (EAPI) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Euroapi S.A. (EAPI) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Paris, France with about 3,000 employees. Its market capitalization is roughly €93 million. In the fiscal year ended 2025-12-31, EAPI reported €853M in revenue and (€211M) in net income.

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

Interactive charts & full statements →

EAPI Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue€853M€919M€1.0B€981M
Gross Profit€145M€142M€165M€177M
Operating Income (EBIT)€2M(€10M)€4M€27M
Net Income(€211M)(€131M)(€190M)(€15M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EAPI Free Cash Flow History

EAPI Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€1.3B€1.5B€1.6B€1.7B
Total Liabilities€516M€506M€685M€626M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EAPI viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← EAGRAll “E” companiesEARTH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.